BioWorld

March 31, 2006

Pharmacopeia, GSK In Deal For Up To $83M Per Program

GlaxoSmithKline plc has discovered a new way of feeding its pipeline through external partnerships; it formed the Center of Excellence for External Drug Discovery (CEEDD) and called on Pharmacopeia Drug Discovery Inc. as its first collaborator. (BioWorld Today) Read More

Amgen, Abgenix Finish BLA For CRC Drug Panitumumab

After TGN1412’s Failure, Safe Deposit Box Now Is Pandora’s

Riding High, Amylin Adding $465M Via Public Stock Sale

Clinical Data Begins Pivotal Study Of Depression Drug

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...